What is CorFlow?
Founded in 2016, CorFlow is dedicated to pioneering diagnostic and therapeutic solutions aimed at restoring healthy microvascular blood flow. The company focuses on critical unmet needs within the human body, positioning itself as a leader in this specialized medical field. CorFlow's commitment to innovation in microvascular health is evident in its pursuit of advanced technologies.
How much funding has CorFlow raised?
CorFlow has raised a total of $48.5M across 1 funding round:
Series B
$48.5M
Series B (2024): $48.5M with participation from Panakes Partners and Broadview Ventures
Key Investors in CorFlow
Panakes Partners
Panakes Partners is a Venture Capital investor that finances medical companies, early stage startups and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields.
Broadview Ventures
Broadview Ventures is focused on impact investing in the field of cardiovascular disease and stroke, aiming to accelerate the development of innovative technologies for diagnosis and treatment. The company engages in targeted investments to bring promising treatments to patients.
What's next for CorFlow?
The recent Series B financing, characterized as a major strategic investment, signals CorFlow's transition into a scaling phase. This capital infusion is expected to accelerate product development, expand market reach, and further solidify its position in the diagnostic and therapeutic solutions sector. The company's trajectory suggests a focus on clinical validation and commercialization efforts.
See full CorFlow company page
